9 METERS BIOPHARMA, INC.
NMTRQHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$42.0M | −$36.8M | −$60.9M | −$25.5M | $18.2M | $11.2M |
| Net income | −$43.8M | −$36.8M | −$61.5M | −$27.0M | −$24.2M | −$11.6M |
| Total assets | $33.1M | $50.2M | $39.2M | $5.3M | $6.5M | $798,489 |
| Total liabilities | $30.7M | $8.6M | $7.0M | $14.9M | — | — |
| Equity | $2.4M | $41.6M | $32.1M | −$9.6M | −$3.7M | −$12.2M |
| EPS (diluted) | $-3.38 | $-3.03 | $-0.58 | — | — | — |
| Shares out. | 258.2M | 216.1M | 41.3M | 26.8M | 25.7M | 8.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −1823.2%
- Return on assets
- −132.0%
- Return on capital (ROCE)
- −1713.6%
- Liabilities / assets
- 92.8%
- Debt / equity
- 12.81×
- Book value / share
- $0.01
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -28.89distress
- Accruals / assets
- −19.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2017
- NT 10-Qmissed a reporting deadline ↗May 16, 2017
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Sensenig BethanyOfficer — Chief Financial Officer | Apr 21, 2023 | Sell | 9,100 | $1.21 |
| Sirgo Mark ADirector | Mar 29, 2023 | Grant | 7,885 | — |
| Rice Yehuda MichaelDirector | Mar 29, 2023 | Grant | 7,885 | — |
| Johnson Lorin KDirector | Mar 29, 2023 | Grant | 7,885 | — |
| Constantino Michael T.Director | Mar 29, 2023 | Grant | 7,885 | — |
| Ventimiglia SamanthaDirector | Mar 29, 2023 | Grant | 7,885 | — |
| Sensenig BethanyOfficer — Chief Financial Officer | Mar 27, 2023 | Grant | 50,177 | — |
| Temperato JohnOfficer — Chief Executive Officer | Mar 27, 2023 | Grant | 68,815 | — |
| Temperato JohnOfficer — Chief Executive Officer | Jul 6, 2022 | Buy | 125,000 | $0.23 |
| Sirgo Mark ADirector | Jul 1, 2022 | Buy | 175,000 | $0.25 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 13,788 | 2.0 | +0.0% |
| Apr 30, 2026 | 13,786 | 4.3 | 0.0% |
| Apr 15, 2026 | 13,786 | 689.3 | 0.0% |
| Mar 31, 2026 | 13,786 | 88.4 | 0.0% |
| Mar 13, 2026 | 13,786 | 5.8 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering event · Delisting / listing-standard notice · Director / officer changeJul 18, 2023
- Delisting / listing-standard noticeJun 16, 2023
- Director / officer changeMay 30, 2023
- Other material eventMay 22, 2023
- Entered a material agreement · Debt acceleration / triggering eventMay 19, 2023
- Results of operationsMay 15, 2023
- Entered a material agreement · Debt acceleration / triggering eventApr 27, 2023
- Entered a material agreement · Delisting / listing-standard noticeApr 6, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.